Ningbo Menovo Pharm Co Ltd Cash Flow Conversion Efficiency
Ningbo Menovo Pharm Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Ningbo Menovo Pharm Co Ltd (603538) has a cash flow conversion efficiency ratio of 0.016x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥38.86 Million ≈ $5.69 Million USD) by net assets (CN¥2.42 Billion ≈ $353.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Ningbo Menovo Pharm Co Ltd market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Ningbo Menovo Pharm Co Ltd (2011–2025)
Cash flow conversion efficiency of Ningbo Menovo Pharm Co Ltd from 2011 to 2025. This chart illustrates how Ningbo Menovo Pharm Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Ningbo Menovo Pharm Co Ltd (603538) share price today for real-time trading data and today's change.
Ningbo Menovo Pharm Co Ltd Cash Flow Conversion Ratio Explained
Ningbo Menovo Pharm Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Ningbo Menovo Pharm Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ningbo Menovo Pharm Co Ltd ranked by their cash flow conversion efficiency. Review 603538 FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Helix Energy Solutions Group Inc
NYSE:HLX
|
0.015x |
|
Capitol Federal Financial Inc
NASDAQ:CFFN
|
0.017x |
|
Altareit
PA:AREIT
|
0.051x |
|
Naruida Technology Co. Ltd. Cl A
SHG:688522
|
N/A |
|
TotalEnergies EP Gabon S.A.
PA:EC
|
0.068x |
|
International General Insurance Holdings Ltd
NASDAQ:IGIC
|
0.162x |
|
LAMDA Development S.A.
AT:LAMDA
|
-0.046x |
|
Cinda Real Estate Co Ltd
SHG:600657
|
-0.002x |
Annual Cash Flow Conversion Efficiency for Ningbo Menovo Pharm Co Ltd (2011–2025)
The table below shows the annual cash flow conversion efficiency of Ningbo Menovo Pharm Co Ltd from 2011 to 2025. Also see Ningbo Menovo Pharm Co Ltd asset portfolio for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.45 Billion ≈ $358.64 Million |
CN¥157.56 Million ≈ $23.06 Million |
0.064x | +51.03% |
| 2024-12-31 | CN¥2.29 Billion ≈ $335.31 Million |
CN¥97.54 Million ≈ $14.27 Million |
0.043x | +918.66% |
| 2023-12-31 | CN¥2.19 Billion ≈ $319.83 Million |
CN¥9.13 Million ≈ $1.34 Million |
0.004x | -96.72% |
| 2022-12-31 | CN¥2.17 Billion ≈ $318.01 Million |
CN¥276.95 Million ≈ $40.53 Million |
0.127x | +14.28% |
| 2021-12-31 | CN¥1.98 Billion ≈ $289.52 Million |
CN¥220.63 Million ≈ $32.28 Million |
0.112x | -21.89% |
| 2020-12-31 | CN¥1.76 Billion ≈ $257.91 Million |
CN¥251.61 Million ≈ $36.82 Million |
0.143x | +24.57% |
| 2019-12-31 | CN¥1.57 Billion ≈ $229.52 Million |
CN¥179.75 Million ≈ $26.30 Million |
0.115x | +229.61% |
| 2018-12-31 | CN¥1.34 Billion ≈ $196.11 Million |
CN¥46.60 Million ≈ $6.82 Million |
0.035x | -49.57% |
| 2017-12-31 | CN¥1.16 Billion ≈ $170.11 Million |
CN¥80.15 Million ≈ $11.73 Million |
0.069x | -57.01% |
| 2016-12-31 | CN¥731.02 Million ≈ $106.97 Million |
CN¥117.24 Million ≈ $17.16 Million |
0.160x | -22.37% |
| 2015-12-31 | CN¥645.81 Million ≈ $94.50 Million |
CN¥133.42 Million ≈ $19.52 Million |
0.207x | +55.00% |
| 2014-12-31 | CN¥564.34 Million ≈ $82.58 Million |
CN¥75.22 Million ≈ $11.01 Million |
0.133x | -56.46% |
| 2013-12-31 | CN¥487.44 Million ≈ $71.33 Million |
CN¥149.21 Million ≈ $21.83 Million |
0.306x | +255.52% |
| 2012-12-31 | CN¥442.58 Million ≈ $64.76 Million |
CN¥38.11 Million ≈ $5.58 Million |
0.086x | -73.22% |
| 2011-12-31 | CN¥378.47 Million ≈ $55.38 Million |
CN¥121.67 Million ≈ $17.80 Million |
0.321x | -- |
About Ningbo Menovo Pharm Co Ltd
Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. The company's products portfolio includes valsartan, losartan, clopidogrel, perindopril, rosuvastatin calcium, atorvastatin calcium, purin bahrain, and other products. It offers APIs, intermediates, and preparations for the treatment of cardiovascular, central nervous system, gastrointestinal t… Read more